BioSpace News Archive

- Lantern has entered into agreements with leading contract manufacturing and process development groups to advance manufacturing and development activities on both LP-300 and LP-184. - The manufacturing and process development activity is expected to start immediately and ensure that sufficient drug candidate material will be available for upcoming clinical trials and ongoing research studies.

Paragonix Technologies, Inc . today announced that its flagship product, Paragonix SherpaPak™ Cardiac Transport System (CTS), is the recipient of a prestigious international design award: the Red Dot Award . This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200720005071/en/ Paragonix SherpaPak CTS is a 2020 Red Dot Award winner for product design

iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Jeffrey Sirek was appointed as Senior Vice President and General Manager of Xoft. “We are very pleased to add Mr. Sirek to our Company. He brings to the team a proven track record of high sales productivity, brand development, marketing success, and revenue growth,” said Stacey Stevens, President of iC

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Mark A. McCamish , MD, PhD, has joined Viracta as a Strategic Advisor to the Company. Dr. McCamish will provide strategic, financial and operational guidance to the Viracta leadership team as the Com

Dalrada Financial Corp. (OTC Pink: DFCO) is announcing to its shareholders and the public that Harvey Hershkowitz was appointed to Dalrada’s Board of Directors.

Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 pivotal trial of cabozantinib (CABOMETYX ® ) in combination with atezolizumab (TECENTRIQ ® ) in patients with inoperable, locally advanced or metastatic renal cell carcinoma (RCC) who progressed during or fo

Dyne Therapeutics , a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of pediatric neurologist Francesco Muntoni, FRCPCH, FMedSci, to its Scientific Advisory Board. Dr. Muntoni is a global leader in clinical research into neuromuscular disease, with particular expertise in clinical care, clinical trial design and drug development for Duchenne

JW Therapeutics , a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, today announced the acquisition of Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS ® antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries. This press rel

Darling Ingredients Inc. (NYSE: DAR), today announced that its Rousselot business, the global leader of collagen-based solutions, has successfully introduced X-Pure® GelMA at Bio Digital 2020.

Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2020 before the market opens on August 5, 2020, and will hold a conference call to discuss the results on August 5, 2020 at 8:00 a.m. Eastern Time. You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID # 4458189.